FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157684762> ?p ?o ?g. }

• W3157684762 endingPage "76" @default.
• W3157684762 startingPage "1" @default.
• W3157684762 abstract "Tranexamic acid safely reduces mortality in traumatic extracranial bleeding. Intracranial bleeding is common after traumatic brain injury and can cause brain herniation and death. We assessed the effects of tranexamic acid in traumatic brain injury patients.To assess the effects of tranexamic acid on death, disability and vascular occlusive events in traumatic brain injury patients. We also assessed cost-effectiveness.Randomised trial and economic evaluation. Patients were assigned by selecting a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients, caregivers and those assessing outcomes were masked to allocation. All analyses were by intention to treat. We assessed the cost-effectiveness of tranexamic acid versus no treatment from a UK NHS perspective using the trial results and a Markov model.175 hospitals in 29 countries.Adults with traumatic brain injury within 3 hours of injury with a Glasgow Coma Scale score of ≤ 12 or any intracranial bleeding on computerised tomography scan, and no major extracranial bleeding, were eligible.Tranexamic acid (loading dose 1 g over 10 minutes then infusion of 1 g over 8 hours) or matching placebo.Head injury death in hospital within 28 days of injury in patients treated within 3 hours of injury. Secondary outcomes were early head injury deaths, all-cause and cause-specific mortality, disability, vascular occlusive events, seizures, complications and adverse events.Among patients treated within 3 hours of injury (n = 9127), the risk of head injury death was 18.5% in the tranexamic acid group versus 19.8% in the placebo group (855/4613 vs. 892/4514; risk ratio 0.94, 95% confidence interval 0.86 to 1.02). In a prespecified analysis excluding patients with a Glasgow Coma Scale score of 3 or bilateral unreactive pupils at baseline, the results were 12.5% in the tranexamic acid group versus 14.0% in the placebo group (485/3880 vs. 525/3757; risk ratio 0.89, 95% confidence interval 0.80 to 1.00). There was a reduction in the risk of head injury death with tranexamic acid in those with mild to moderate head injury (166/2846 vs. 207/2769; risk ratio 0.78, 95% confidence interval 0.64 to 0.95), but in those with severe head injury (689/1739 vs. 685/1710; risk ratio 0.99, 95% confidence interval 0.91 to 1.07) there was no apparent reduction (p-value for heterogeneity = 0.030). Early treatment was more effective in mild and moderate head injury (p = 0.005), but there was no obvious impact of time to treatment in cases of severe head injury (p = 0.73). The risk of disability, vascular occlusive events and seizures was similar in both groups. Tranexamic acid is highly cost-effective for mild and moderate traumatic brain injury (base case of £4288 per quality-adjusted life-year gained).Early tranexamic acid treatment reduces head injury deaths. Treatment is cost-effective for patients with mild or moderate traumatic brain injury, or those with both pupils reactive.Further trials should examine early tranexamic acid treatment in mild head injury. Research on alternative routes of administration is needed.Time to treatment may have been underestimated.Current Controlled Trials ISRCTN15088122, ClinicalTrials.gov NCT01402882, EudraCT 2011-003669-14, Pan African Clinical Trial Registry PACTR20121000441277.The project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 26. See the NIHR Journals Library website for further project information. In addition, funding was provided by JP Moulton Charitable Trust, Joint Global Health Trials (Medical Research Council, Department for International Development and the Wellcome Trust). This project was funded by the NIHR Global Health Trials programme.Traumatic brain injury is a leading cause of death and disability worldwide, with over 60 million new cases each year. When the head is injured there is often bleeding inside the brain, which can continue for some time and worsen after hospital admission. This bleeding increases pressure inside the skull, causing further damage to the brain, which can be fatal or result in serious disability. Tranexamic acid is a cheap drug that reduces bleeding in other conditions. A large trial of accident victims (other than those with head injury) found that it reduced the chances of bleeding to death. We wanted to find out if tranexamic acid would also reduce deaths among patients with head injuries. We studied just under 13,000 patients with traumatic brain injury who did not have other major injuries to their bodies from 175 hospitals across 29 countries. Patients were assigned at random to receive either tranexamic acid or a dummy medicine called a placebo. Neither the clinical team nor the patient knew which medicine the patient received. All patients received the usual treatments given to head-injured patients. Outcomes from 9127 participants were analysed. Among patients treated early, within 3 hours, the rate of head injury death was 18.5% (855/4613) in the tranexamic acid group and 19.8% (892/4514) in the placebo group. We found no evidence of an effect of tranexamic acid overall. However, in patients with mild or moderate traumatic brain injury, there was a 20% reduction in deaths. There were no side effects and no increase in disability in survivors when the drug was used. The economic analysis shows that tranexamic acid represents value for money for patients with mild or moderate traumatic brain injury." @default.
• W3157684762 created "2021-05-10" @default.
• W3157684762 creator A5006218186 @default.
• W3157684762 creator A5007428949 @default.
• W3157684762 creator A5008829549 @default.
• W3157684762 creator A5009907000 @default.
• W3157684762 creator A5011884491 @default.
• W3157684762 creator A5012471875 @default.
• W3157684762 creator A5013400897 @default.
• W3157684762 creator A5021185078 @default.
• W3157684762 creator A5021561251 @default.
• W3157684762 creator A5030708501 @default.
• W3157684762 creator A5030861804 @default.
• W3157684762 creator A5032782760 @default.
• W3157684762 creator A5040169514 @default.
• W3157684762 creator A5040704503 @default.
• W3157684762 creator A5047972775 @default.
• W3157684762 creator A5055216712 @default.
• W3157684762 creator A5056861966 @default.
• W3157684762 creator A5070366254 @default.
• W3157684762 creator A5078620136 @default.
• W3157684762 creator A5079520595 @default.
• W3157684762 date "2021-04-01" @default.
• W3157684762 modified "2023-10-16" @default.
• W3157684762 title "Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT" @default.
• W3157684762 cites W1173240736 @default.
• W3157684762 cites W1594364707 @default.
• W3157684762 cites W1601964757 @default.
• W3157684762 cites W175489226 @default.
• W3157684762 cites W1774861407 @default.
• W3157684762 cites W1813475664 @default.
• W3157684762 cites W1903132268 @default.
• W3157684762 cites W1939149497 @default.
• W3157684762 cites W1980300082 @default.
• W3157684762 cites W1982305254 @default.
• W3157684762 cites W1983199628 @default.
• W3157684762 cites W1987604733 @default.
• W3157684762 cites W2000829740 @default.
• W3157684762 cites W2021231736 @default.
• W3157684762 cites W2027592211 @default.
• W3157684762 cites W2028627947 @default.
• W3157684762 cites W2035363671 @default.
• W3157684762 cites W2039315505 @default.
• W3157684762 cites W2041745554 @default.
• W3157684762 cites W2060765641 @default.
• W3157684762 cites W2061152996 @default.
• W3157684762 cites W2061997164 @default.
• W3157684762 cites W2062396905 @default.
• W3157684762 cites W2065793617 @default.
• W3157684762 cites W2075952240 @default.
• W3157684762 cites W2092108751 @default.
• W3157684762 cites W2103798426 @default.
• W3157684762 cites W2105459922 @default.
• W3157684762 cites W2106449742 @default.
• W3157684762 cites W2111548427 @default.
• W3157684762 cites W2119342009 @default.
• W3157684762 cites W2120440553 @default.
• W3157684762 cites W2120737609 @default.
• W3157684762 cites W2123578204 @default.
• W3157684762 cites W2152268156 @default.
• W3157684762 cites W2162132892 @default.
• W3157684762 cites W2162249417 @default.
• W3157684762 cites W2184439882 @default.
• W3157684762 cites W2202419144 @default.
• W3157684762 cites W2253325314 @default.
• W3157684762 cites W2302970224 @default.
• W3157684762 cites W2325601152 @default.
• W3157684762 cites W2340669326 @default.
• W3157684762 cites W2346022404 @default.
• W3157684762 cites W2395279856 @default.
• W3157684762 cites W2402981146 @default.
• W3157684762 cites W2522738478 @default.
• W3157684762 cites W2524045616 @default.
• W3157684762 cites W2563317648 @default.
• W3157684762 cites W2767208517 @default.
• W3157684762 cites W2801625478 @default.
• W3157684762 cites W2822610530 @default.
• W3157684762 cites W2883332335 @default.
• W3157684762 cites W2905467422 @default.
• W3157684762 cites W2912993810 @default.
• W3157684762 cites W2995699817 @default.
• W3157684762 cites W3081909612 @default.
• W3157684762 cites W4211043869 @default.
• W3157684762 cites W4247907436 @default.
• W3157684762 cites W4292528167 @default.
• W3157684762 cites W4299584209 @default.
• W3157684762 doi "https://doi.org/10.3310/hta25260" @default.
• W3157684762 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8107835" @default.
• W3157684762 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33928903" @default.
• W3157684762 hasPublicationYear "2021" @default.
• W3157684762 type Work @default.
• W3157684762 sameAs 3157684762 @default.
• W3157684762 citedByCount "10" @default.
• W3157684762 countsByYear W31576847622022 @default.
• W3157684762 countsByYear W31576847622023 @default.
• W3157684762 crossrefType "journal-article" @default.
• W3157684762 hasAuthorship W3157684762A5006218186 @default.
• W3157684762 hasAuthorship W3157684762A5007428949 @default.

• next